US 11,883,478 B2
Method of treatment
Yaela Baine, Philadelphia, PA (US); and Jacqueline Miller, Philadelphia, PA (US)
Assigned to GLAXOSMITHKLINE BIOLOGICALS S.A., Rixensart (BE)
Appl. No. 14/777,985
Filed by GLAXOSMITHKLINE BIOLOGICALS S.A., Rixensart (BE)
PCT Filed Mar. 17, 2014, PCT No. PCT/EP2014/055355
§ 371(c)(1), (2) Date Sep. 17, 2015,
PCT Pub. No. WO2014/147044, PCT Pub. Date Sep. 25, 2014.
Claims priority of provisional application 61/874,008, filed on Sep. 5, 2013.
Claims priority of provisional application 61/802,918, filed on Mar. 18, 2013.
Prior Publication US 2016/0279225 A1, Sep. 29, 2016
Int. Cl. A61K 39/095 (2006.01); A61K 39/102 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/095 (2013.01) [A61K 39/102 (2013.01); A61K 2039/55 (2013.01); A61K 2039/6037 (2013.01); A61K 2039/70 (2013.01); Y02A 50/30 (2018.01)] 40 Claims
 
1. A method of immunising against Neisseria meningitidis infection, comprising the steps of:
(a) immunising a human patient at a first age of between 0 and 6 months with a bacterial saccharide conjugate vaccine comprising bacterial saccharides each separately conjugated to tetanus toxoid carrier proteins, wherein the bacterial saccharides consist essentially of (i) a N. meningitidis serogroup C (MenC) capsular saccharide and a Haemophilus influenza (Hib) saccharide or (ii) a N. meningitidis serogroup C (MenC) capsular saccharide, a N. meningitidis serogroup Y (MenY) capsular saccharide and a Haemophilus influenza (Hib) saccharide, and wherein the tetanus toxoid carrier protein is present at a total TT content of 5-40 idg per dose; and
(b) immunising the human patient at a second age of between 13 and 20 months with a Neisseria meningitidis conjugate vaccine comprising N. meningitidis serogroup A capsular saccharide (MenA), N. meningitidis serogroup C capsular saccharide (MenC), N. meningitidis serogroup W135 capsular saccharide (MenW135), and N. meningitidis serogroup Y capsular saccharide (MenY) conjugated separately to a tetanus toxoid carrier protein which is present at a total dose of 30-80 μg, wherein the Neisseria meningitidis conjugate vaccine is co-administered with a vaccine comprising diphtheria, tetanus, and acellular pertussis antigens (DTPa),
wherein co-administration of the Neisseria meningitidis conjugate vaccine with the vaccine comprising DTPa in step b) results in an at least 10% increase in immunogenicity against at least one of MenA, MenC, MenW135, and MenY compared to where the Neisseria meningitidis conjugate vaccine is administered alone, measured by Serum Bacteriocidal Assay (SBA).